Recommendations will help organizations that appraise new drugs establish whether their use will result in longer-term benefits for patients

Four health technology assessment agencies, including Canada’s Drug Agency, have published new guidance on the use of surrogate endpoints in cost-effectiveness analysis to inform decision-making when evaluating new medicines.

Canada’s Drug Agency is seeking to expand the group of scientists who contribute their expertise to our organization and help us power evidence-informed health technology decisions.

Consultation status: Closed
Consultation period: January 6 to February 6, 2025

Canada’s Drug Agency is outlining additional plans to modernize the drug reimbursement review process and is seeking feedback on our proposed approaches.